GlassScriptPhysician profile
Tyler Alansky
NPI 1902588189
$764.27
in general payments reported to CMS, 2019-2025
9 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $69.74 · 2024: $396 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $285.61 | 2023-2025 | Xiidra, Miebo, Infuse |
| Alcon Vision LLC | $168.25 | 2023-2025 | Total30, Precision7, Rocklatan |
| Coopervision INC. | $156.12 | 2023-2025 | Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $32.78 | 2025 | Xdemvy |
| Dompe US, INC. | $30.84 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $29.56 | 2025 | |
| Abb Con-Cise Optical Group LLC | $23.26 | 2024 | Contact Lens, Spectacle Lenses |
| Oyster Point Pharma, INC. | $19.48 | 2024 | Tyrvaya |
| Abbvie INC. | $18.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Alansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.